Pharmaxi Revenue and Competitors

Wroclaw,

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Pharmaxi's estimated annual revenue is currently $4.8M per year.(i)
  • Pharmaxi's estimated revenue per employee is $201,000

Employee Data

  • Pharmaxi has 24 Employees.(i)
  • Pharmaxi grew their employee count by 4% last year.

Pharmaxi's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M2305%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M1223%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M180%$114.3MN/A
#8
$7.2M36-20%N/AN/A
#9
$13.7M68-7%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is Pharmaxi?

Pharmaxi is innovative company introducing new technologies in project setting, data collection and monitoring of various clinical project for pharmaceutical industry. We successfully combine the experience and energy of experts in IT, project management, clinical databases, biostatistics and integrated services in the clinical trials governance. We provide the industry with know-how automated software systems for clinical trials conduction that dramatically improves the quality and timelines of projects. Our innovative approach to the organization and conduct of large-scale non-interventional studies and registries displays their level of evidence and quality to an entirely new orbit. Our extensive experience in clinical research and in the creation of integrated software solutions to satisfy the highest expectations of the customer.

keywords:N/A

N/A

Total Funding

24

Number of Employees

$4.8M

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Pharmaxi News

2022-03-30 - Top Startups Initiated by the Ukrainians

Pharmaxi was founded in 2013. Headquarters are in Kyiv, Ukraine. Size range: 11-50. Founder(s): Yurii Lebid Pharmaxi is a medical and clinical...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.3M25N/AN/A
#2
$2.7M27-7%N/A
#3
$1.4M288%N/A
#4
$1.8M31-6%$2.1M
#5
$3.7M3252%N/A